drugset

drugset / Trial / NCT00762684

Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

NCT00762684 ↗

Phase 3 Terminated 8 enrolled Takeda

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in treating subjects with type 2 diabetes mellitus.

Timeline

Start: 2004-11
Primary completion: 2004-12
Completion: 2004-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMIGLITAZAR	Small molecule	32 mg	Oral

Indications